An Inside Look At the Long Battle to Legalize Psychedelics: Dr. Rick Doblin, Founder & Executive Director of MAPS

“I know it's hard for people to think about holding on if they're in despair, but there's the possibility of healing coming ahead. Don’t give up hope,” says Dr. Rick Doblin, who has devoted his career to getting MDMA and other psychedelics approved by the FDA.  As you’ll hear in this episode of Raise the Line, he could be on the verge of seeing his decades-long dream come true.  On the day host Shiv Gaglani spoke to Doblin (January 5, 2023) successful results from a Phase 3 clinical trial of MDMA to treat PTSD were released by the Multidisciplinary Association for Psychedelic Studies – an organization Doblin founded thirty-six years ago. This sets in motion a process that could result in FDA approval of MDMA for this use in 2024. That’s very good news for the millions of Americans with PTSD – and hundreds of millions worldwide – whose disease is resistant to other treatments. One of the next big steps is training therapists to incorporate these drugs into their work, something MAPS and other organizations are moving quickly to accomplish. Tune into this fascinating conversation about the political and social factors that have held up legalization of psychedelics for decades, other promising applications of MDMA, what fuels Doblin’s passion for normalizing the use of these promising medications, and the largest ever conference on psychedelics coming to Denver, Colorado in June.  Mentioned in this episode:https://maps.org/https://psychedelicscience.org/ If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast